Global Opioid Use Disorder (OUD) Market Insights Forecasts to 2032

• The Global Opioid Use Disorder (OUD) Market Size was valued at USD 2.8 Billion in 2022.
• The Market Size is Growing at a CAGR of 10.7% from 2022 to 2032.
• The Worldwide Opioid Use Disorder (OUD) Market size is expected to reach USD 7.8 Billion by 2032.
• Asia Pacific is expected To Grow the fastest during the forecast period.

 

Get more details on this report -

Request Free Sample PDF

 

The Global Opioid Use Disorder (OUD) Market Size is expected to reach USD 7.8 Billion by 2032, at a CAGR of 10.7% during the forecast period 2022 to 2032.

 

Market Overview

Opioids are synthetically produced in labs to replicate the chemical features of opioids, which interact with opioid receptors on nerve cells in the body and brain to alleviate pain. They are a class of medications that includes prescription pain relievers, synthetic opioids, and heroin. Prescription opioids are intended to be used to manage acute pain, such as that caused by an injury or surgery, chronic pain, active-phase cancer therapy, palliative care, and end-of-life care. Many patients rely on prescribed opioids to help them manage their ailments while under the care of a doctor. Opioid use disorder is a chronic lifetime condition with major potential effects such as impairment, relapses, and death.

 

Report Coverage

This research report categorizes the global opioid use disorder (OUD) market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global opioid use disorder (OUD) market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global opioid use disorder (OUD) market. Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market.

 

Driving Factors

A growing number of patients are suffering from severe and chronic diseases such as cancer, cardiovascular disease, pain from accidents, and other disorders. These disorders frequently induce persistent pain, which is controlled with the use of medicines, primarily opioids. While the pain decreases, the patient is more likely to get hooked to these medicines. These medicines increase dependence and sudden termination may result in withdrawal symptoms in the patient. Moreover, another major aspect driving market development is the growing involvement of governmental and non-governmental groups in raising awareness about opioid overdose and its associated consequences. The number of opioid users has grown substantially, prompting many groups to take a more comprehensive strategy to treat the problem. Several countries have increased their efforts to support patients and decrease the burden of opioid addiction. For example, the Department of Health and Human Services (HHS) announced funding for substance abuse prevention and treatment programs in March 2022. The decision was made to increase access to medication-assisted therapy for opioid use disorder and to prevent prescription drug abuse.

 

Restraining Factors

The adverse effects of the medications used to treat opioid addiction are expected to hinder the market all over the projected period. These medications commonly cause muscular pains, vomiting, diarrhea, constipation, respiratory difficulties, bone/joint pain, bladder discomfort, and stomach cramps. In severe circumstances of a drug's bad response, the patient may also suffer from depression and other psychological issues. Furthermore, the risks connected with these treatments have resulted in a warning by the US FDA, which has a negative influence on the drug class, minimizing the use of pharmaceuticals in the treatment of OUD.

 

Market Segmentation

• In 2022, the buprenorphine segment is influencing the market with the largest market share over the forecast period.

Based on the drug class, the global opioid use disorder (OUD) market is segmented into buprenorphine, methadone, and naltrexone. Among these segments, the buprenorphine segment is dominating the market with the largest revenue share during the forecast period owing to the increased usage of buprenorphine as an effective choice to treat opioid dependency, reduce cravings, and enhance the quality of life for patients undergoing addiction treatment accounts for the largest proportion of the market. Currently, buprenorphine is available in two formulations: alone and in conjunction with the opioid receptor antagonist naloxone. Both buprenorphine formulations are useful in the treatment of opioid use disorders.

 

• In 2022, the parenteral segment is dominating the largest market share during the forecast period.

Based on the route of administration, the global opioid use disorder (OUD) market is bifurcated into different categories such as oral and parenteral. Among these segments, the parenteral segment is dominating the market owing to the availability of several types of OUD medications in varied doses in parenteral form. As a result, the parenteral mode of medication delivery retains its dominance in the worldwide market.

 

The oral sector is expected to account for a lesser share of the worldwide Opioid Use Disorder market. However, it is predicted to develop significantly since many people choose oral medicine delivery over injection.

 

• In 2022, the hospitals segment is dominating the largest market share during the forecast period.

Based on the distribution channel, the global opioid use disorder (OUD) market is classified into hospitals, private clinics, Homecare & others. Among these segments, hospitals are dominating the market due to the patient population being reliant on this channel for the administration of parenteral OUD medications such as buprenorphine.

 

The retail pharmacies & shops category is expected to be the second-largest segment in the future years due to the patient population's reliance on these sites to fill prescriptions.

 

Regional Segment Analysis of the opioid use disorder (OUD) market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

 

North America dominated the market with the largest market revenue of over 49.3% during the forecast period

 

Get more details on this report -

Request Free Sample PDF

 

North America is leading the significant market growth over the forecast period due to a rise in the number of product releases for the treatment of opioid use disorder, an increase in opioid prescriptions, an increase in opioid consumers, an increase in opioid overdose fatalities, and a well-established opioid business in North America.

 

Asia Pacific is expected to experience high revenue market growth during the forecast period due to the figure of elderly people, growth in the awareness about accessibility of healthcare facilities, and escalation in the number of chronic disorders.

 

Competitive Analysis

The report offers the appropriate analysis of the key organizations/companies involved within the global opioid use disorder (OUD) market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Indivior PLC
• Alkermes
• Orexo AB
• Titan Pharmaceuticals, Inc.
• Mallinckrodt Pharmaceuticals
• BioDelivery Sciences International Inc.
• Viatris Inc. (Mylan N.V.)
• Hikma Pharmaceuticals PLC
• Camurus

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Development

• In April 2023, the New York State Department of Health (DOH) and the New York State Office of Addiction Services and Supports (OASAS) announced the introduction of the Buprenorphine Assistance Pilot Program to help with the expense of buprenorphine for opioid use disorder (OUD) treatment.

 

• In June 2022, Titan Pharmaceuticals, Inc. partnered with Indegene to launch a multichannel digital marketing campaign across the United States and expand its expertise in supplying Probuphine implants to opioid addiction patients.

 

• In March 2022, Collegium Pharmaceutical, Inc. completed the purchase of BioDelivery Sciences International Inc.

 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2022 to 2032. Spherical Insights has segmented the Global Opioid Use Disorder (OUD) Market based on the below-mentioned segments:

 

Global Opioid Use Disorder (OUD) Market, By Drug Class

• Buprenorphine
• Methadone
• Naltrexone

 

Global Opioid Use Disorder (OUD) Market, By Route of Administration

• Oral 
• Parenteral

 

Global Opioid Use Disorder (OUD) Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Stores
• Online Pharmacies

 

Opioid Use Disorder (OUD) Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico

• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa